AI is discovering more potential drugs than ever. This start-up wants to figure out which ones matter.
SMRTR summary
AI tools are generating more potential drug candidates than ever, but testing and characterizing each one remains slow and costly. Startup 10x Science, founded by Stanford-trained researchers, raised $4.8 million to solve this bottleneck using AI-powered mass spectrometry analysis. Their platform speeds up molecular characterization, helping drug developers quickly identify which candidates are worth pursuing — without requiring expensive equipment or specialized expertise.
SMRTR provides this summary for quick context. The original article belongs to TechCrunch.
Read the original article